Get the Stockscreener App
4.12
5.64%
0.22
After Hours:
4.12
Moleculin Biotech Inc stock is traded at $4.12, with a volume of 192.67K.
It is up +5.64% in the last 24 hours and down -43.09% over the past month.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
See More
Previous Close:
$3.90
Open:
$3.93
24h Volume:
192.67K
Relative Volume:
0.65
Market Cap:
$8.53M
Revenue:
-
Net Income/Loss:
$-29.77M
P/E Ratio:
-0.2694
EPS:
-15.2954
Net Cash Flow:
$-24.23M
1W Performance:
+24.10%
1M Performance:
-43.09%
6M Performance:
-51.53%
1Y Performance:
-90.79%
1-Day Range:
$3.8635
$4.3172
1-Week Range:
$3.17
$4.3172
52-Week Range:
$3.13
$91.25
Moleculin Biotech Inc Stock (MBRX) Company Profile
Name
Moleculin Biotech Inc
Sector
Industry
Phone
713-300-5160
Address
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
4.12 | 8.07M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-25 | Resumed | H.C. Wainwright | Buy |
| Feb-12-25 | Downgrade | Maxim Group | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
Moleculin Biotech Inc Stock (MBRX) Latest News
Moleculin shares rise 6% as enrollment nears key milestone in AML trial - MSN
Moleculin Biotech’s Wild Ride: Is Tiny-Cap MBRX the Next Viral Moonshot or Total Trap? - AD HOC NEWS
MBRX stock touches 52-week low at $1.46 amid sharp yearly decline - MSN
Moleculin Biotech enters inducement offer agreements - MSN
Moleculin Biotech Inc. (MBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Moleculin Biotech begins dosing subjects in combination therapy trial for AML - MSN
Moleculin Biotech amends warrants and reports stockholders’ equity above $10 million - Investing.com Nigeria
Moleculin Biotech amends warrants and reports stockholders’ equity above $10 million By Investing.com - Investing.com South Africa
Moleculin Biotech Amends Warrants to Boost Nasdaq Compliance - TipRanks
Moleculin Biotech Signs Warrant Amendment Agreements With Holders of Series E, F and G Warrants - TradingView — Track All Markets
Moleculin Biotech shares slide after release of pediatric brain tumor trial data - MSN
Why retail investors favor Moleculin Biotech Inc. stockJuly 2025 Movers & Weekly Momentum Stock Picks - Улправда
Will Moleculin Biotech Inc. stock rally after Fed decisions2025 Volatility Report & Long Hold Capital Preservation Tips - Улправда
Will Moleculin Biotech Inc. stock split attract more investorsMarket Performance Report & Safe Capital Growth Plans - Улправда
Moleculin Biotech Earnings Notes - Trefis
Moleculin Biotech (LTS:0K2H) EV-to-OCF : -0.07 (As of Dec. 19, 2025) - GuruFocus
How risky is Moleculin Biotech Inc. (MOL) stock compared to peersJuly 2025 Spike Watch & Target Return Focused Picks - DonanımHaber
Why Moleculin Biotech Inc. (MOL) stock is listed among top recommendationsJuly 2025 PreEarnings & Technical Pattern Based Signals - DonanımHaber
Earnings Report: Why Moleculin Biotech Inc. stock is considered a top pickJuly 2025 Snapshot & Weekly Setup with High ROI Potential - Улправда
Market Review: Why Moleculin Biotech Inc. stock could rally in 2025July 2025 Snapshot & Fast Gain Swing Alerts - DonanımHaber
Why Moleculin Biotech Inc. stock remains a top recommendationJuly 2025 PostEarnings & Weekly Breakout Watchlists - Улправда
What technical charts say about Moleculin Biotech Inc. stockMarket Risk Analysis & Smart Swing Trading Alerts - DonanımHaber
Why Moleculin Biotech Inc. stock could rally in 2025Global Markets & Verified Momentum Stock Watchlist - DonanımHaber
Aug Wrap: Why Moleculin Biotech Inc. stock is considered a top pickJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - Улправда
Why Moleculin Biotech Inc. stock is popular among millennialsWeekly Market Outlook & High Accuracy Swing Trade Signals - Улправда
Why hedge funds are buying Moleculin Biotech Inc. stockTrade Risk Summary & Accurate Trade Setup Notifications - ulpravda.ru
Moleculin Biotech reports positive phase 1 trial results - MSN
Moleculin Biotech stock falls after pediatric brain tumor trial results By Investing.com - Investing.com Australia
Moleculin Biotech’s Bold Move: Stock Split Announced - StocksToTrade
Moleculin’s brain cancer drug shows promise in pediatric trial By Investing.com - Investing.com Nigeria
Moleculin Shares Drop 17% Despite Positive Phase 1 WP1066 Data In Pediatric Brain Tumors - Nasdaq
Moleculin Biotech Prepares for 1-for-25 Reverse Split Amidst Clinical Advancements - timothysykes.com
Moleculin Biotech regains Nasdaq compliance - MSN
Moleculin's WP1066 Shows Immune Activity, Favorable Safety In Pediatric Brain Cancer Trial - Nasdaq
Moleculin announces positive phase 1 data for WP1066 in pediatric brain tumors - marketscreener.com
Moleculin Biotech’s Reverse Split Shocks Market - timothysykes.com
Moleculin’s brain cancer drug shows promise in pediatric trial - Investing.com
Moleculin Biotech stock falls after pediatric brain tumor trial results - Investing.com
Moleculin Biotech Reports Positive Phase 1 Trial Results - TipRanks
Moleculin Biotech Reports Positive Phase 1 Trial Results for WP1066 in Pediatric Brain Cancer Treatments - Quiver Quantitative
Moleculin Biotech, Inc. Announces Positive Phase 1 Trial Results for WP1066 - TradingView — Track All Markets
Moleculin Announces Positive Results from Phase 1 Clinical - GlobeNewswire
Moleculin Biotech (NASDAQ: MBRX) highlights positive Phase 1 pediatric brain tumor trial - Stock Titan
Moleculin Biotech regains compliance with Nasdaq minimum bid price rule By Investing.com - Investing.com Nigeria
Moleculin Biotech Regains Nasdaq Compliance - TipRanks
Moleculin Biotech Inc Stock (MBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moleculin Biotech Inc Stock (MBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KLEMP WALTER V | CEO and President |
Jun 23 '25 |
Buy |
0.37 |
675,675 |
250,000 |
743,607 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):